Shots:

• The P-III (FLAURA2) study assesses Tagrisso (80mg, QD, oral) + CT (pemetrexed: 500mg/m^2 + cisplatin: 75mg/m^2 or carboplatin), Q3W followed by Tagrisso with pemetrexed maintenance as a 1L treatment of patients (n=557) with locally advanced (stage IIIB-IIIC) or metastatic (stage IV) EGFRm NSCLC
• The study depicted an improved PFS & a favorable trend in the OS interim results at 41% data maturity with consistent outcomes in the subgroups such as sex, race, type of EGFRm & age. Further OS evaluation continues for the final analysis
• The combination of Tagrisso & CT also demonstrated consistent benefit in time to first subsequent treatment, time to progression on 2L therapy & time to 2nd subsequent treatment

Ref: AstraZeneca | Image: AstraZeneca 

Related News:- AstraZeneca’s Tagrisso Receives Approval from the US FDA for the Treatment of Advanced Lung Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com